The company in question is, bluebird bio, Inc. (NASDAQ:BLUE) currently with a stock price of 57.43 (-11.97% today). The market cap for bluebird bio, Inc. is 2436.71, and is in the sector Healthcare, and Biotechnology industry. The target price for bluebird bio, Inc. is 85.69. Currently bluebird bio, Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for bluebird bio, Inc. is 1141.94 and so far today it is 2592422.
Performance in the last year for bluebird bio, Inc. has been -19.42%. For EPS growth, bluebird bio, Inc. has seen a growth of -162.20%, and is looking to grow in the next year to -6.60%. More long term stats show that EPS growth has been *TBA over the last five years and could be *TBA for the next five years. bluebird bio, Inc. has seen sales growth quarter over quarter at -67.30%, with EPS growth quarter over quarter at -1.30%. The 20-day simple moving average is -5.96%, with the 200-day simple moving average coming to 14.60%.
Since the IPO date for bluebird bio, Inc. on the 6/19/2013, bluebird bio, Inc. has seen performance year to date to be 1.59%. With bluebird bio, Inc. trading at 57.43, the dividend yield is *TBA, and the EPS is -5.58.
So could bluebird bio, Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 420.12 and the P/B is at 3.17. The P/cash is 4.23, with P/free cash flow at *TBA.
bluebird bio, Inc. ability to deal with debt shows that the current ratio is 14.4, and the quick ratio is 14.4. This is with long term debt/equity at 0.11, and total debt/equity at 0.11.
In terms of margins, bluebird bio, Inc. has a gross margin of *TBA, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for bluebird bio, Inc. is *TBA. Return on assets come to -20.80% with return on investment coming to -18.50%.
Insider ownership for bluebird bio, Inc., is at 1.10% and institutional ownership comes to 98.10%. Outstanding shares are at 37.35. While shares float is 36.8. The float short is currently 24.21%, and short ratio is 7.8.